ClinicalTrials.gg
CompletedNCT03670953Updated Feb 9, 2023Results posted

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

A Phase 3 interventional study of IR CD-LD and IPX203 ER CD-LD in Parkinson's Disease (Disorder), sponsored by Impax Laboratories, LLC. Completed at 108 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
Largest of 14
630 · median 77
Started
2018
the only one that year
Phase 3
7 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one has the largest enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 12th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's disease (PD) who have motor fluctuations.

Read the detailed description

This was a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study. The study consisted of a 3-week, open-label IR CD-LD dose adjustment period; a 4-week, open-label period for conversion to IPX203; followed by a 13-week double-blind treatment period with participants randomized in a 1:1 ratio, stratified by center, to receive either IPX203 (with matching IR CD-LD placebo) or IR CD-LD (with matching IPX203 placebo).

03

Conditions studied

  • Parkinson's Disease (Disorder)

Browse trials for

Keywords

  • Idiopathic Parkinson's Disease
  • Lewy Body Parkinson's Disease
  • Paralysis Agitans
  • Primary Parkinsonism
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants diagnosed at age ≥ 40 years with PD, consistent with the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria and who are being treated with stable regimens of CD-LD but experiencing motor fluctuations.
  • Able to provide written prior to the conduct of any study-specific procedures.
  • Female participants of must have a negative urine pregnancy test at Screening Visit.
  • Negative urine screen for drugs of abuse and negative alcohol breath test at Screening.
  • Hoehn and Yahr Stages 1, 2, 3, or 4 in the "On" state (part of Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III)
  • Agrees to use a medically acceptable method of throughout the study and for 6 weeks after completing the study. Medically acceptable methods of contraception that may be used by the participant and/or partner include but are not limited to: abstinence, oral contraception, NuvaRing or transdermal systems, diaphragm with vaginal spermicide, intrauterine device, condom and partner using vaginal spermicide, surgical sterilization (6 months), progestin implant or injection, or female (no menstrual period for ˃ 2 years) or vasectomy (˃ 6 months).
  • (MoCA) score ≥ 24 at Screening Visit in "On" state.
  • Able to differentiate "On" state from "Off" state as determined by at least 75% concordance with a trained rater in "On/Off" ratings for 8 ratings over a 4-hour training period. The concordance must include at least 1 "On" and 1 "Off" rating and must be achieved within two 4-hour training sessions.
  • Able and willing to comply with the protocol, including completion of diaries and availability for all study visits.
  • Responsive to CD-LD therapy and currently being treated on a stable regimen with CD-LD for at least 4 weeks prior to Visit 1.
  • At Screening, the participant has predictable "Off" periods.

Exclusion criteria

Exclusion Criteria:

  • Received any medications within 30 days or 5 times the half-life, whichever is longer, prior to Visit 1.
  • Female participants who are currently breastfeeding or lactating.
  • Had prior neurosurgical treatment for PD or if such procedure is planned or anticipated during the study period.
  • Allergic to any in the study drugs.
  • History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy, proximal small-bowel resection, or bariatric surgery.
  • History of upper gastrointestinal hemorrhage in participants with peptic ulcer disease within the past 5 years.
  • History of glaucoma with intraocular pressures that are elevated despite appropriate medical management.
  • History of seizure or epilepsy and experienced at least 1 seizure during the past 12 months or has not been compliant with medically recommended therapy or visits.
  • History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias that are not controlled with medical and/or surgical interventions. A recent (≤ 12 months) history of myocardial infarction with secondary arrhythmias is exclusionary regardless of the therapeutic control.
  • History of neuroleptic malignant syndrome or of nontraumatic rhabdomyolysis.
  • Liver enzyme values ≥ 2.5 times the ; or history of severe hepatic impairment.
  • Serum creatinine level ≥ 1.75 times the upper limit of normal; or requires dialysis at the time of Screening.
  • Participant with a history of malignant melanoma or with a suspicious undiagnosed skin lesion which in the opinion of the investigator could be melanoma.
  • History of drug or alcohol abuse within the 12 months prior to Screening.
  • Received within 4 weeks of Screening or planning to take during participation in the clinical study:
  • Any doses of a CR CD-LD apart from a single daily bedtime dose, any doses of Rytary, additional CD (eg, Lodosyn) or benserazide (eg, Serazide), or catechol-O-methyl transferase inhibitors (entacapone or tolcapone) or medications containing these inhibitors (Stalevo),
  • Nonselective monoamine oxidase inhibitors (MAOI), apomorphine, or antidopaminergic agents, including antiemetics.
  • Employees or family members of the investigator, study site, or sponsor.
  • Participants who have previously participated in an IPX203 study.
  • Participants who, in the opinion of the clinical investigator, should not participate in the study.
  • Based on clinical assessment, participant does not adequately comprehend the terminology needed to complete the PD diary.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
630 participants (actual)

Study arms

  • Active comparator
    IR CD-LD - Dose Adjustment

    Participants started on the same dose as the pre-study dosing regimen of IR CD-LD and then received dose adjusted IR CD-LD tablets daily orally, for a period of 3 weeks. If the participant was taking controlled release carbidopa-levodopa (CR CD-LD), the CR CD-LD was discontinued and substituted with a 1:1 milligram-equivalent dose of IR CD-LD.

    Drug: IR CD-LD

  • Experimental
    IPX203 - Dose Conversion

    Participants received extended release (ER) CD-LD (IPX203) capsules orally, every 6 - 12 hours for a period of 4 weeks at a dose based on their most frequent stable dose of IR CD-LD in dose adjustment period. Participant with most frequent stable dose of 25-100 milligrams (mg) IR CD-LD received 70 - 280 mg IPX203 thrice daily (TID); \>25-100 - 37.5-150 mg IR CD-LD received 105-420 mg IPX203 TID; \>37.5-150 - 50-200 mg IR CD-LD received 140-560 mg IPX203 TID; \>50 - 200 mg IR CD-LD received 175-700 mg IPX203 TID. Participants who received a daily total dose of less than 125-500 mg IR CD-LD in dose adjustment received IPX203 every 12 hours. After initial dose conversion from IR CD-LD to IPX203 as per above mentioned dose conversion schedule, the dose of IPX203 could be further adjusted during the 4 week dose conversion period.

    Drug: IPX203 ER CD-LD

  • Experimental
    IPX203 - Double-Blind Maintenance

    Participants received IPX203 capsules orally, every 6 - 12 hours for 13 weeks at a stable dose established at the end of dose conversion period along with placebo matched to IR CD-LD.

    Drug: IPX203 ER CD-LD · Other: Placebo Matching IPX203

  • Active comparator
    IR CD-LD - Double -Blind Maintenance

    Participants received IR CD-LD tablets daily orally, for 13 weeks at a stable dose established at the end of dose adjustment period along with placebo matched to IPX203.

    Drug: IR CD-LD · Other: Placebo Matching IR CD-LD

Interventions

  • DrugIR CD-LD

    Active comparator - IR CD-LD

    Also known as: Generic for Sinemet tablets

  • Investigational formulation - ER CD-LD

  • OtherPlacebo Matching IPX203

    Double dummy placebo capsules

  • OtherPlacebo Matching IR CD-LD

    Double dummy placebo tablets

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET)

    "Good on" time was derived from the 3-day PD Diaries. For each day, "Good on" time was calculated by adding the number of half-hour intervals in which either an "On" without dyskinesia or "On" with nontroublesome dyskinesia was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization. Least square mean (LSM), standard error (SE), confidence interval (CI), Mixed model repeated measures (MMRM), Change from baseline (CFB).

    Time frame: Baseline (Week 7) and Week 20/ET

Secondary outcomes

  1. Change From Baseline in "Off" Time Per Day at Week 20/ET

    "Off" time was derived from the 3-day PD Diaries. For each day, "Off" time was calculated by adding the number of half-hour intervals in which the Status "Off" was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

    Time frame: Baseline (Week 7) and Week 20/ET

  2. Percentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET

    The Patient Global Impression of Change (PGIC) is self assessment questionnaire which was used by participants to compare his/her condition on a 7-point scale ranging from 1-Very Much Worse, 2-Much Worse, 3-Minimally Worse, 4-No Change, 5-Minimally Improved, 6-Much Improved, 7-Very Much Improved. Percentage of participants with either "Much Improved" or "Very Much Improved" was reported.

    Time frame: Week 20/ET

  3. Change From Baseline in The Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Week 20/ET

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). Part III score ranges from 0 to 136. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

    Time frame: Baseline (Week 7) and Week 20/ET

  4. Change From Baseline in The Sum of MDS-UPDRS Part II and Part III at Week 20/ET

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). The scale range for Part II+III score is 0-188. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

    Time frame: Baseline (Week 7) and Week 20/ET

07

Results

Posted Feb 9, 2023

Participant flow

A total of 630 enrolled participants entered the immediate release carbidopa-levodopa (IR CD-LD) dose adjustment period of which 589 participants entered IPX203 conversion period of which 506 participants entered double-blind maintenance period. Participants were randomized in a 1:1 ratio in double blind period.

Dose Adjustment (Weeks 1- 3)
Participant flow — Dose Adjustment (Weeks 1- 3)
MilestoneIR CD-LD - Dose AdjustmentIPX203 - Dose ConversionIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Started630000
Completed589000
Not completed41000
Withdrew: Adverse event4000
Withdrew: Lack of efficacy1000
Withdrew: Protocol violation6000
Withdrew: Withdrawal by subject9000
Withdrew: Miscellaneous21000
Dose Conversion (Weeks 4 - 7)
Participant flow — Dose Conversion (Weeks 4 - 7)
MilestoneIR CD-LD - Dose AdjustmentIPX203 - Dose ConversionIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Started058900
Completed050600
Not completed08300
Withdrew: Adverse event03500
Withdrew: Lack of efficacy01000
Withdrew: Protocol violation0100
Withdrew: Non compliance0200
Withdrew: Lost to follow-up0100
Withdrew: Withdrawal by subject03200
Withdrew: Miscellaneous0200
Double Blind Maintenance (Weeks 8 - 20)
Participant flow — Double Blind Maintenance (Weeks 8 - 20)
MilestoneIR CD-LD - Dose AdjustmentIPX203 - Dose ConversionIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Started00256250
Completed00222227
Not completed003423
Withdrew: Adverse event00143
Withdrew: Lack of efficacy0058
Withdrew: Protocol violation0031
Withdrew: Non compliance0010
Withdrew: Withdrawal by subject001011
Withdrew: Miscellaneous0010

Outcome measures

PrimaryMean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET)

"Good on" time was derived from the 3-day PD Diaries. For each day, "Good on" time was calculated by adding the number of half-hour intervals in which either an "On" without dyskinesia or "On" with nontroublesome dyskinesia was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization. Least square mean (LSM), standard error (SE), confidence interval (CI), Mixed model repeated measures (MMRM), Change from baseline (CFB).

Time frame:
Baseline (Week 7) and Week 20/ET
Reported as:
Mean · hours/day
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET)
hours/dayIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Baseline (Week 7)11.67 ± 2.94311.72 ± 2.759
Change at Week 20/ET-0.39 ± 2.706-0.97 ± 3.081
Statistical analysis
  • IPX203 - Double-Blind Maintenance vs IR CD-LD - Double -Blind Maintenance · MMRM · p = 0.0194 (LSM, SE, CI and p-value from a MMRM with CFB in "Good on" time as outcome, baseline "Good on" time as a covariate, treatment and visit as fixed effects, pooled center as random effect and a treatment-by-visit interaction.) · Least squares mean difference: 0.53 · 95% CI 0.09 to 0.97The degree-of-freedom of the denominator is estimated using the Kenward-Roger method. Unstructured covariance structure is assumed.
SecondaryChange From Baseline in "Off" Time Per Day at Week 20/ET

"Off" time was derived from the 3-day PD Diaries. For each day, "Off" time was calculated by adding the number of half-hour intervals in which the Status "Off" was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

Time frame:
Baseline (Week 7) and Week 20/ET
Reported as:
Mean · hours/day
Change From Baseline in "Off" Time Per Day at Week 20/ET
hours/dayIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Baseline (Week 7)3.95 ± 2.5244.02 ± 2.466
Change at Week 20/ET0.29 ± 2.2350.76 ± 2.901
Statistical analysis
  • IPX203 - Double-Blind Maintenance vs IR CD-LD - Double -Blind Maintenance · MMRM · p = 0.0252 (LSM, SE, CI and p-value from a MMRM with CFB in "Off" time as outcome, baseline "Off" time as a covariate, treatment and visit as fixed effects, pooled center as random effect and a treatment-by-visit interaction.) · Least squares mean difference: -0.48 · 95% CI -0.90 to -0.06The degree-of-freedom of the denominator is estimated using the Kenward-Roger method. Unstructured covariance structure is assumed.
SecondaryPercentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET

The Patient Global Impression of Change (PGIC) is self assessment questionnaire which was used by participants to compare his/her condition on a 7-point scale ranging from 1-Very Much Worse, 2-Much Worse, 3-Minimally Worse, 4-No Change, 5-Minimally Improved, 6-Much Improved, 7-Very Much Improved. Percentage of participants with either "Much Improved" or "Very Much Improved" was reported.

Time frame:
Week 20/ET
Reported as:
Number · percentage of participants
Percentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET
percentage of participantsIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Percentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET29.718.8
Statistical analysis
  • IPX203 - Double-Blind Maintenance vs IR CD-LD - Double -Blind Maintenance · Cochran-Mantel-Haenszel · p = 0.0015 (P-value from the Cochran-Mantel-Haenszel test stratified by pooled center comparing the percentage of "Much" or "Very Much Improved" participants between the treatment groups.) · Percent difference: 10.9 · 95% CI 3.5 to 18.3
SecondaryChange From Baseline in The Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Week 20/ET

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). Part III score ranges from 0 to 136. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

Time frame:
Baseline (Week 7) and Week 20/ET
Reported as:
Mean · score on a scale
Change From Baseline in The Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Week 20/ET
score on a scaleIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Baseline (Week 7)26.9 ± 16.6227.0 ± 16.83
Change at Week 20/ET1.1 ± 11.070.9 ± 10.10
Statistical analysis
  • IPX203 - Double-Blind Maintenance vs IR CD-LD - Double -Blind Maintenance · MMRM · p = 0.9587 (LSM, SE, CI and p-value from a MMRM with CFB in MDS-UPDRS Part III Score as outcome, baseline MDS-UPDRS Part III Score as a covariate, treatment and visit as fixed effects, pooled center as random effect and a treatment-by-visit interaction.) · Least squares mean difference: 0.0 · 95% CI -1.8 to 1.7The degree-of-freedom of the denominator is estimated using the Kenward-Roger method. Unstructured covariance structure is assumed.
SecondaryChange From Baseline in The Sum of MDS-UPDRS Part II and Part III at Week 20/ET

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). The scale range for Part II+III score is 0-188. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.

Time frame:
Baseline (Week 7) and Week 20/ET
Reported as:
Mean · score on a scale
Change From Baseline in The Sum of MDS-UPDRS Part II and Part III at Week 20/ET
score on a scaleIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Baseline (Week 7)38.9 ± 22.2039.3 ± 21.65
Change at Week 20/ET2.0 ± 13.541.8 ± 12.39
Statistical analysis
  • IPX203 - Double-Blind Maintenance vs IR CD-LD - Double -Blind Maintenance · MMRM · p = 0.9668 (LSM, SE, CI \& p-value from MMRM with CFB in MDS-UPDRS Part II \& III Scores as outcome, baseline MDS-UPDRS Part II and III Scores as a covariate, treatment and visit as fixed effects, pooled center as random effect \& a treatment-by-visit interaction.) · Least squares mean difference: 0.0 · 95% CI -2.2 to 2.1The degree-of-freedom of the denominator is estimated using the Kenward-Roger method. Unstructured covariance structure is assumed.

Adverse events

Collected over From first dose up to 30 days after last dose (Up to Weeks 24). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IR CD-LD - Dose Adjustment0/630 (0%)7/630 (1.1%)40/630 (6.3%)
IPX203 - Dose Conversion0/589 (0%)12/589 (2%)130/589 (22.1%)
IPX203 - Double-Blind Maintenance0/256 (0%)8/256 (3.1%)35/256 (13.7%)
IR CD-LD - Double -Blind Maintenance0/250 (0%)4/250 (1.6%)32/250 (12.8%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventIR CD-LD - Dose AdjustmentIPX203 - Dose ConversionIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
Atrioventricular block completeCardiac disorders0/6300/5890/2561/250
Cardiac failureCardiac disorders0/6300/5890/2561/250
Urinary tract infectionInfections and infestations0/6301/5890/2561/250
Back painMusculoskeletal and connective tissue disorders0/6300/5890/2561/250
Benign prostatic hyperplasiaReproductive system and breast disorders0/6300/5890/2561/250
BradycardiaCardiac disorders0/6300/5891/2560/250
AstheniaGeneral disorders0/6300/5891/2560/250
FatigueGeneral disorders0/6300/5891/2560/250
PyelonephritisInfections and infestations0/6300/5891/2560/250
Ejection fraction descreasedInvestigations0/6300/5891/2560/250
Most frequent other events
Showing 10 of 11
Most frequent other events
EventIR CD-LD - Dose AdjustmentIPX203 - Dose ConversionIPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind Maintenance
DyskinesiaNervous system disorders11/63040/5895/2561/250
NauseaGastrointestinal disorders7/63029/58911/2562/250
Dry mouthGastrointestinal disorders2/63025/5893/2562/250
FallInjury, poisoning and procedural complications6/63013/5895/2569/250
Urinary tract infectionInfections and infestations1/6307/5894/2568/250
DizzinessNervous system disorders3/63017/5896/2562/250
Back painMusculoskeletal and connective tissue disorders3/6306/5892/2567/250
AnxietyPsychiatric disorders1/6309/5897/2560/250
VomitingGastrointestinal disorders3/63013/5893/2560/250
InsomniaPsychiatric disorders6/63013/5892/2561/250

Baseline characteristics

The Safety Analysis Set included all participants who were treated with any study drug.

Age, Continuous
Age, Continuous(years)IPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind MaintenanceNot RandomizedTotal
Mean66.1 ± 9.0266.5 ± 8.8567.3 ± 9.0066.5 ± 8.95
Sex: Female, Male
Sex: Female, Male(Participants)IPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind MaintenanceNot RandomizedTotal
Female977364234
Male15917760396
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind MaintenanceNot RandomizedTotal
Hispanic or Latino32311477
Not Hispanic or Latino223215106544
Unknown or Not Reported1449
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IPX203 - Double-Blind MaintenanceIR CD-LD - Double -Blind MaintenanceNot RandomizedTotal
American Indian or Alaska Native3003
Asian53210
Native Hawaiian or Other Pacific Islander0000
Black or African American2316
White244242120606
More than one race0000
Unknown or Not Reported2215
08

Study locations

108 sites
  • Xenoscience, Inc. (102)
    Phoenix, Arizona 85004, United States
  • St. Joseph's Hospital & Medical Center/ Barrow Neurological Institute (156)
    Phoenix, Arizona 85013, United States
  • Clinical Trials, Inc. (113)
    Little Rock, Arkansas 72205, United States
  • University of Arkansas for Medical Sciences (117)
    Little Rock, Arkansas 72205, United States
  • Loma Linda University Health Care, Department of Neurology (137)
    Loma Linda, California 92354, United States
  • Keck School of Medicine of USC/University of Southern California (106)
    Los Angeles, California 90033, United States
  • Hoag Memorial Hospital Presbyterian (134)
    Newport Beach, California 92663, United States
  • SC3 Research - Pasadena (148)
    Pasadena, California 91105, United States
  • SC3 Research - Reseda (146)
    Reseda, California 91335, United States
  • University of Colorado Hospital Anschutz Outpatient Pavilion (120)
    Aurora, Colorado 80045, United States
  • Rocky Mountain Movement Disorders Center (116)
    Englewood, Colorado 80113, United States
  • Christiana Care Neurology Specialists (153)
    Newark, Delaware 19713, United States
  • JEM Research Institute (136)
    Atlantis, Florida 33462, United States
  • Visionary Investigators Network (168)
    Aventura, Florida 33180, United States
  • University of Miami-UHealth at Boca Raton (152)
    Boca Raton, Florida 33131, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton (121)
    Boca Raton, Florida 33486, United States
  • MD Clinical (111)
    Hallandale Beach, Florida 33009, United States
  • Infinity Clinical Research (104)
    Hollywood, Florida 33024, United States
  • University of Florida Health Science Center(129)
    Jacksonville, Florida 32209, United States
  • Neurology Associates, P.A. (125)
    Maitland, Florida 32751, United States
  • University of Miami (149)
    Miami, Florida 33136, United States
  • Medical Professional Clinical Research Center, INC (163)
    Miami, Florida 33165, United States
  • Parkinsons's Disease Treatment Center of Southwest Florida (131)
    Port Charlotte, Florida 33980, United States
  • Infinity Clinical Research, LLC (105)
    Sunrise, Florida 33351, United States
  • University of South Florida (114)
    Tampa, Florida 33613, United States
  • Premiere Research Institute at Palm Beach Neurology (174)
    West Palm Beach, Florida 33407, United States
  • Charter Research (166)
    Winter Park, Florida 32792, United States
  • Emory Brain Health Center (110)
    Atlanta, Georgia 30329, United States
  • NeuroStudies.net, LLC (155)
    Decatur, Georgia 30033, United States
  • Northwestern Medical Group Neurology Clinic(145)
    Chicago, Illinois 60611, United States
  • Central DuPage Hospital (151)
    Winfield, Illinois 60190, United States
  • Indiana University Health Neuroscience Center (164)
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center (118)
    Kansas City, Kansas 66160, United States
  • Quest Research Institute (103)
    Farmington Hills, Michigan 48334, United States
  • Henry Ford West Bloomfield Hospital (100)
    West Bloomfield, Michigan 483222, United States
  • Struthers Parkinson's Center (130)
    Golden Valley, Minnesota 55427, United States
  • Washington University (109)
    Saint Louis, Missouri 63110, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health (142)
    Las Vegas, Nevada 89106, United States
  • Roseman Medical Research Institute/Roseman Medical Group (154)
    Las Vegas, Nevada 89118, United States
  • Albany Medical College (139)
    Albany, New York 12208, United States
  • Mount Sinai West-Department of Neurology(172)
    New York, New York 10019, United States
  • Wake Forest Baptist Health Sciences (127)
    Winston-Salem, North Carolina 27157, United States
  • Ucgni (133)
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center (123)
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic (144)
    Cleveland, Ohio 44195, United States
  • University of Toledo, Gardner-McMaster Parkinson Center (122)
    Toledo, Ohio 43614, United States
  • Movement Disorder Clinic of Oklahoma (115)
    Tulsa, Oklahoma 74136, United States
  • Medical University of South Carolina (150)
    Charleston, South Carolina 29425, United States
  • The Vanderbilt Clinic(158)
    Nashville, Tennessee 37232, United States
  • Neurology Consultants of Dallas, PA (108)
    Dallas, Texas 75251, United States
  • University of Texas Southwestern Medical Center (143)
    Dallas, Texas 75390-9184, United States
  • Houston Methodist Neurological Institute/Movement Disorders Clinic (135)
    Houston, Texas 77030, United States
  • Inova Medical Group-Neurology I (147)
    Alexandria, Virginia 22311, United States
  • VCU Health - Neuroscience, Orthopaedic and Wellness Center (124)
    Henrico, Virginia 23233, United States
  • Booth Gardner Parkinson's Care Center (112)
    Kirkland, Washington 98034, United States
  • Inland Northwest Research (119)
    Spokane, Washington 99202, United States
  • Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704)
    Brno, 65691, Czechia
  • Neurohk, s.r.o (701)
    Choceň, 56501, Czechia
  • Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702)
    Pardubice, 53203, Czechia
  • Clintrial s.r.o. (703)
    Praha 10, 10000, Czechia
  • AXON Clinical, s.r.o. (700)
    Praha 5, 15000, Czechia
  • Neurologicka ordinace FORBELI s.r.o.(706)
    Praha 6, 160 00, Czechia
  • CHU de Clermont-Ferrand - Hopital Gabriel Montpied (404)
    Clermont-Ferrand Cedex 1, 63003, France
  • CHU de Montpellier, Hopital Gui de Chauliac(405)
    Montpellier Cedex 5, 34295, France
  • Centre Hospitalier Universitaire de Nice (400)
    Nice, 06002, France
  • INSERM, Centre d'investigation Clinique 1402, CHU de Poitiers (402)
    Poitiers Cedex, 86021, France
  • Centre d'Investigation Clinique 1436-CHU Purpan-Hopital Pierre Paul Riquet (403)
    Toulouse Cedex 9, 31059, France
  • Curiositas ad sanum, Studien und Beratungs GmbH(311)
    München, Bavaria 80331, Germany
  • Klinikum rechts der lsar der TUM, Klinik und Poliklinik fur Neurologie (303)
    München, Bavaria 81675, Germany
  • Kliniken Beelitz GmbH, Neurologisches Fachkrankenhaus fUr Bewegungsstorungen/Parkinson (300)
    Beelitz-Heilstatten, Brandenburg 14547, Germany
  • Gemeinschaftspraxis Dr. med. Joachim Springub/ Wolfgang Schwarz, Studienzentrum Nord-West (306)
    Westerstede, Lower Saxony 26655, Germany
  • St. Josef-Hospital, Universitatsklinik fur Neurologie, Klinisches Forschungszentrum fur Neurodegeneration (301)
    Bochum, North Rhine-Westphalia 44791, Germany
  • Klinik Haag i. OB, Geriatric Hospital (305)
    Haag In Oberbayern, Oberbayern (Upper Bavaria) 83527, Germany
  • Universitatsklinikum Carl Gustav Carus, Klinik und Poliklinik fur Neurologie (307)
    Dresden, Saxony 01307, Germany
  • Dr. med. REINHARDT Ehret Neurologie Berlin Schlobstr. 29 (309)
    Berlin, 12163, Germany
  • Department "G.F. Ingrassia" Section of neuroscience-Policlinico "Vittorio Emanuele" (608)
    Catania, Italy/Catania/Sicily 95123, Italy
  • Universita G. D'annunzio CeSi Met (604)
    Chieti, Italy/Chieti/Abbruzzo 66100, Italy
  • Centro Ricerca Parkinson San Raffaele Cassino (601)
    Cassino, Italy/Frosinone/Lazio 03043, Italy
  • Fondazione lstituto Neurologico Nazionale "C. Mondino" (606)
    Pavia, Italy/Pavia/Lombardia 27100, Italy
  • Azienda Ospedaliero-Universitaria Pisana (602)
    Pisa, Italy/Pisa/Toscana 56126, Italy
  • University of Rome Tor Vergata/Hospital Tor Vergata (605)
    Roma, Italy/Roma/Lazio 00133, Italy
  • IRCCS San Raffaele Pisana (600)
    Roma, Italy/Roma/Lazio 00163, Italy
  • Department of Neuroscience, Mental Health and Sensory System (NeSMOS), Sapienza University (603)
    Roma, Italy/Roma/Lazio 00189, Italy
  • Centrum Medyczne Neuromed (803)
    Bydgoszcz, 85-163, Poland
  • Szpital Sw. Rozy (805)
    Kraków, 30-394, Poland
  • Krakowska Akademia Neurologii Sp. z o.o.(802)
    Kraków, 31-505, Poland
  • NZOZ Neuromed M. i M Nastaj Spolka Partnerska(800)
    Lublin, 20-064, Poland
  • NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801)
    Poznań, 61-853, Poland
  • Neuro-Care Sp. z o.o. sp. k.(804)
    Siemianowice Śląskie, 41-100, Poland
  • Centrum Medyczne NeuroProtect (806)
    Warszawa, 01-684, Poland
  • Hospital Genral Universitario de Elche (509)
    Elche, Alicante 03203, Spain
  • Hospital Universitari General de Catalunya (504)
    Sant Cugat Del Vallès, Barcelona 08190, Spain
  • Hospital Universitari Mutua Terrassa (506)
    Terrassa, Barcelona 08222, Spain
  • Policlinica Gipuzkoa, S.A.,(511)
    San Sebastian, Gipuzkoa 20014, Spain
  • Clinica Universidad de Navarra (512)
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Quiron Dexeus (501)
    Barcelona, 08028, Spain
  • Hospital Universitario Vall d' Hebron (505)
    Barcelona, 08035, Spain
  • Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516)
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona (507)
    Barcelona, 08036, Spain
  • Hospital De La Santa Creu i Sant Pau (502)
    Barcelona, 08041, Spain

Showing the first 100 of 108 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Jun 2021, 31 months.

Results were first posted in Feb 2023, 1 year 7 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 31 months is close to that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2018
First posted
Sep 14, 2018
StartActual
Nov 6, 2018
Primary completionActual
Jun 15, 2021
CompletionActual
Jun 15, 2021
Results first posted
Feb 9, 2023
Last update
Feb 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03670953
Responsible party
Sponsor
First posted
Sep 14, 2018
Start date
Nov 6, 2018
Primary completion
Jun 15, 2021
Completion
Jun 15, 2021
Results posted
Feb 9, 2023
Last update
Feb 9, 2023

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPX203

Start the discussion